Dr. Ramchandren is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1924 Alcoa Highway
Knoxville, TN 37920Phone+1 865-305-8780- Is this information wrong?
Summary
- I am a board certified hematologist oncologist specializing in the care of patients with lymphoma with a clinical and research interest in Hodgkin lymphoma. In particular I am interested in novel therapies for treatment of lymphoma and am involved in numerous clinical trials.
Education & Training
Ascension Providence/MSUCHMFellowship, Hematology and Medical Oncology, 2005 - 2008
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2001 - 2004
Ross University School of MedicineClass of 2001
Certifications & Licensure
TN State Medical License 2019 - 2025
MI State Medical License 2005 - 2022
MD State Medical License 2004 - 2005
PA State Medical License 2001 - 2004- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- leukemia lymphoma society man of the year candidate leukemia lymphoma society of Michigan, 2014
Clinical Trials
- A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2013 Nov 29
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
- A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Oct 15
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsCardiac Amyloid Detection by PET/CT Imaging of Iodine (I) Evuzamitide (I-p5+14): A Phase 1/2 Study.Jonathan S Wall, Emily B Martin, Ronald Lands, Radhakrishnan Ramchandren, Alan Stuckey, R Eric Heidel, Bryan Whittle, Dustin Powell, Tina Richey, Angela D Williams, Ja...> ;JACC. Cardiovascular Imaging. 2023 Nov 1
- 6 citationsThe iRregimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, ...> ;Eclinicalmedicine. 2023 Feb 1
- Editorial: Advances in the treatment of Hodgkin lymphoma.Matthew Mei, Guilherme Perini, Radhakrishnan Ramchandren> ;Frontiers in Oncology. 2023 Jan 1
- Join now to see all
Journal Articles
- Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin LymphomaPatrick B. Johnston, Radhakrishnan Ramchandren, Lauren C. Pinter-Brown, BioMed Central
Abstracts/Posters
- Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124I-p5+14, for Imaging Systemic AmyloidosisRadhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 StudyRadhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaRadhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- ASCO 2018: Dr. Radhakrishnan Ramchandren on the North American Results of the Frontline AAVD StudyJune 2018
Press Mentions
Nivolumab in Newly Diagnosed Advanced cHLSeptember 20th, 2019
Nivolumab for Newly Diagnosed AdvancedApril 8th, 2019
OncLive® Presents the Latest State of the Science Summit™ on Hematologic MalignanciesSeptember 5th, 2018- Join now to see all
Hospital Affiliations
University of Tennessee Medical CenterKnoxville, Tennessee
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
